Stocks making the biggest moves midday: SpaceX, Lumentum, Huntsman, e.l.f. Beauty, Intel & more

Midday trading was driven by a mix of company-specific catalysts, led by Rackspace's 9% jump on an AMD capacity agreement and Gildan Activewear's 24% plunge after a negative short report. Other notable movers included SpaceX up 11% after its $135 IPO price and trading debut, Huntsman down 17% on its all-stock merger with Olin, and Dave & Buster's down 5% after a Q1 earnings miss. Several stocks also moved on product launches, FDA action, analyst target changes, and layoffs, while chip shares broadly sold off with SMH down nearly 3%.

Analysis

The clearest signal is not the day’s price moves but the rotation beneath them: investors are taking profits in the crowded AI/semis complex while rewarding idiosyncratic, cash-generative stories and corporate actions. That usually marks a short-term digestion phase rather than an end to the AI trade, but it does imply weaker near-term beta for suppliers with the most stretched positioning. AMD’s deal is strategically useful, yet the market is treating it as supply commitment without enough evidence of incremental margin accretion, which is why the downstream beneficiaries are being sold into strength rather than chased.

The more interesting second-order effect is on AI infrastructure vendors: if hyperscaler and enterprise budgets are still real, the pullback in GLW/LITE/COHR looks more like positioning relief than a fundamental reset. However, these names are more vulnerable than the chip leaders because they trade on a narrower narrative stack and can re-rate sharply on any delay in deployment schedules. For the industrial merger, the market is signaling skepticism that synergies can outrun cyclicality; all-stock deals in chemicals typically transfer balance-sheet risk to the target holders and can compress the acquirer’s multiple for months if end-demand stays soft.

On the consumer side, execution beats are still being rewarded, but product-launch upside is likely faster to monetize than airline optimization or broker cost cuts. The apparel short could remain a squeeze candidate if the negative report is not quickly validated, but fundamentals matter here: when a stock gaps down 20%+, the first 48 hours often decide whether it becomes an opportunistic mean-reversion or a new leg lower. In healthcare, regulatory acceptance is a cleaner catalyst than commercial rollout, so the move in GILD is more defensible over a 3-6 month horizon than the market is currently pricing.

Key Decisions for Investors

• Fade the AI/semis bounce tactically: short a basket of AVGO/LRCX/MU/INTC vs long cash-rich defensives for 1-2 weeks; risk/reward favors a continuation of position unwinds after a 3-day run, with a stop if SMH reclaims its 20-day trend.
• Buy GLW or COHR on further weakness only if volume normalizes; otherwise avoid chasing the dip. Best expression is a 1-3 month call spread sized small, since the setup is about sentiment reset more than immediate earnings revision.
• Consider a short HUN / long OLN pair for 3-6 months: the all-stock merger reduces near-term upside in HUN while OLN should be less exposed to integration disappointment; use tight risk controls around deal-spread moves.
• Take a starter long in GILD on any post-news consolidation, with a 3-6 month view. The setup is asymmetric because regulatory acceptance can re-rate the name before broad sell-side models catch up.
• Avoid chasing ELF after the pop; wait for post-launch confirmation at Target/TikTok shop. If sales data confirms traction, use a 1-2 month call spread; if not, momentum can unwind quickly once novelty fades.